ijms-logo

Journal Browser

Journal Browser

Special Issue "Noncoding RNAs as New Instruments in the Orchestration of Cell Death and Cancer Therapy Resistance 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 15 December 2021.

Special Issue Editors

Dr. Silvia Zappavigna
E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania “L. Vanvitelli” via L. De Crecchio 7, 80138 Naples, Italy
Interests: cell death mechanisms; microRNAs; long non coding RNAs; biomarkers; nanotechnology; drug delivery; signal transduction; target therapy; cancer; circulating tumor cells; glioblastoma; prostate cancer; hepatocellular cancer
Dr. Amalia Luce
E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania “L. Vanvitelli” via L. De Crecchio 7, 80138 Naples, Italy
Interests: microRNAs; long non-coding RNAs; extracellular vesicles; regulation of gene expression; cell death mechanisms; cell signaling; cancer therapy; drug delivery systems; target therapy; immunotherapy; prostate cancer; colorectal cancer; glioblastoma
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Noncoding RNAs (ncRNAs) are emerging as key orchestrators of tumorigenesis. Recent advances in biotechnologies, such as high-throughput sequencing, genome editing, and mouse modeling, have allowed for functional studies of ncRNAs to provide new perspectives in the fight against cancer. In addition to miRNAs and lncRNAs, that play a key role in the regulation of gene expression, other novel ncRNAs, such as transfer RNA (tRNA) fragments, snoRNA-related lncRNAs (sno-lncRNAs), and circRNAs have also appeared on the radar of cancer researchers. Increasing evidence shows that ncRNAs function either as tumor suppressors or oncogenes by regulating one or several cancer hallmarks, including evading cell death, metastasis, and drug resistance. Cancer therapy resistance is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis. The mechanisms of therapy resistance are complex and result from multiple factors. Among them, ncRNAs have been shown to regulate drug resistance by targeting drug resistance-related genes or influencing genes related to cell proliferation and cell death. Indeed, ncRNAs target and inhibit the expression of several cellular regulators, including those controlling programmed cell death via the intrinsic and extrinsic, p53-, and endoplasmic reticulum (ER) stress-induced apoptotic pathways, as well as pathways of necroptosis, mitophagy, and autophagy.

This Special issue will focus on the recent advances in “Noncoding RNAs as New Instruments in the Orchestration of Cell Death and Cancer Therapy Resistance”, including new findings concerning ncRNAs that modulate apoptosis, autophagy, and other programmed cell death and cancer resistance pathways, as well as emerging data on miRNA–lncRNA interactions that affect cell death regulation and mechanisms of resistance to therapy. Current research progress on ncRNAs for clinical and/or potential translational applications, including the identification of novel therapeutic approaches for ncRNA targeting and delivery strategies, will be also appreciated. 

Dr. Silvia Zappavigna
Dr. Amalia Luce
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • regulatory ncRNAs
  • cell death mechanisms
  • cancer therapy
  • cancer resistance
  • ncRNA based-therapy
  • ncRNA deregulation
  • delivery strategies
  • miRNA/lncRNA interactions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma
Int. J. Mol. Sci. 2021, 22(20), 11168; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222011168 - 16 Oct 2021
Viewed by 216
Abstract
Osteosarcoma has a poor prognosis due to chemo-resistance and/or metastases. Increasing evidence shows that long non-coding RNAs (lncRNAs) can play an important role in drug sensitivity and cancer metastasis. Using osteosarcoma cell lines, we identified a positive correlation between the expression of a [...] Read more.
Osteosarcoma has a poor prognosis due to chemo-resistance and/or metastases. Increasing evidence shows that long non-coding RNAs (lncRNAs) can play an important role in drug sensitivity and cancer metastasis. Using osteosarcoma cell lines, we identified a positive correlation between the expression of a lncRNA and ANRIL, and resistance to two of the three standard-of-care agents for treating osteosarcoma—cisplatin and doxorubicin. To confirm the potential role of ANRIL in chemosensitivity, we independently inhibited and over-expressed ANRIL in osteosarcoma cell lines followed by treatment with either cisplatin or doxorubicin. Knocking-down ANRIL in SAOS2 resulted in a significant increase in cellular sensitivity to both cisplatin and doxorubicin, while the over-expression of ANRIL in both HOS and U2OS cells led to an increased resistance to both agents. To investigate the clinical significance of ANRIL in osteosarcoma, we assessed ANRIL expression in relation to clinical phenotypes using the osteosarcoma data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset. Higher ANRIL expression was significantly associated with increased rates of metastases at diagnosis and death and was a significant predictor of reduced overall survival rate. Collectively, our results suggest that the lncRNA ANRIL can be a chemosensitivity and prognosis biomarker in osteosarcoma. Furthermore, reducing ANRIL expression may be a therapeutic strategy to overcome current standard-of-care treatment resistance. Full article
Show Figures

Figure 1

Back to TopTop